RBMS1 Loss Enables PD-L1 Blockade in TNBC

2026-09-22

The reference study identifies the RNA-binding protein RBMS1 as a post-transcriptional regulator of PD-L1 stability in immune-cold triple-negative breast cancer. By linking RBMS1 to B4GALT1-dependent PD-L1 glycosylation, the work provides a mechanistic rationale for combining RBMS1 depletion with checkpoint or CAR-T approaches to improve antitumor T-cell activity.

RCN2 Drives ESCC Metastasis and Cisplatin Resistance

2026-09-22

This study identifies RCN2 as a driver of esophageal squamous cell carcinoma metastasis and cisplatin resistance through UBR5-dependent ubiquitination and degradation of PPP2CA, which sustains PI3K-AKT signaling. Its integrated clinical, proteomic, biochemical, and in vivo evidence defines the RCN2-UBR5-PPP2CA axis as a mechanistic target for resistance-focused cancer research.

SFI Inhibits Glioma via SRC/PI3K/AKT Signaling

2026-09-21

This study integrates network pharmacology with cell-based and mouse experiments to explain how Shenqi Fuzheng injection suppresses glioma proliferation and migration. Its central finding is that SRC/PI3K/AKT signaling provides a mechanistic link between the multi-component formulation and reduced tumor-cell growth, S-phase progression, epithelial–mesenchymal transition-associated migration, and subcutaneous tumor development.

PEG 400, Quercetin, and BCRP-Mediated Exposure

2026-09-21

The reference study integrates pharmacokinetics, spatial mass spectrometry imaging, transporter assays, and an inflammation model to explain how PEG 400 improves quercetin exposure and activity. Its findings connect solubility, UGT1A9-mediated metabolism, and BCRP/MRP2 efflux, while also defining important limits for translating excipient effects across species and disease models.

T7 RNA Polymerase for Therapeutic mRNA Design

2026-09-20

T7 RNA Polymerase is a high-specificity in vitro transcription enzyme for producing research-grade RNA from engineered DNA templates. This article connects promoter and template design with practical quality decisions, using localized p21 mRNA delivery in bladder cancer as a translational case study.

Cyclic Pifithrin-α hydrobromide: p53 workflows

2026-09-19

Cyclic Pifithrin-α hydrobromide is a reversible chemical tool for testing how p53 activity shapes apoptosis, growth arrest, and DNA-damage responses. This guide translates its established cancer-cell and irradiation applications into controlled workflows, while defining a cautious strategy for exploring links to trigeminal neuroinflammation.

Cross-Kingdom Promoters for E. coli and Yeast

2026-09-18

The reference study develops modular hybrid expression elements that combine bacterial and yeast transcriptional and translation-initiation signals for use in Escherichia coli and Saccharomyces cerevisiae. Its promoter set provides weak, moderate, and strong expression with comparatively consistent behavior across the two hosts and supports coordinated prodeoxyviolacein biosynthesis.

Dlin-MC3-DMA for RNA LNP Workflows

2026-09-18

Dlin-MC3-DMA is a benchmark ionizable cationic liposome for translating siRNA and mRNA concepts into reproducible lipid nanoparticle experiments. This guide connects formulation design, machine-learning-assisted screening, hepatic gene silencing, and practical troubleshooting while separating literature-backed findings from workflow starting points.

LLY-507: An Assay-First SMYD2 Guide

2026-09-17

LLY-507 is a selective SMYD2 inhibitor for dissecting substrate methylation, cancer phenotypes, and fibrosis biology. This assay-first guide connects biochemical potency with cellular controls and explains how renal fibrosis evidence can sharpen experimental design without overstating translational maturity.

Precision Cleavage for Nuclear Architecture

2026-09-17

A mechanistic and translational guide to using PreScission Protease (PSP) to improve fusion-protein workflows investigating dKeap1, lamin Dm0, chromatin architecture, and nuclear condensates.

Luteolin-SME: P-Gp Efflux Inhibition and Bioavailability

2026-09-16

AZD0156: Reframing ATM Inhibition in Cancer Research

2026-09-16

AZD0156 offers a selective way to interrogate ATM-dependent DNA damage signaling while exploring an emerging connection between DNA repair, checkpoint control, and nutrient scavenging. This thought-leadership guide translates mechanistic evidence into practical strategies for cancer therapy research and translational assay design.

Grazoprevir Hydrate: Mechanism & HCV Evidence

2026-09-15

Grazoprevir hydrate, also called MK-5172 hydrate, is an oral HCV NS3/4A protease inhibitor that blocks viral polyprotein processing. Evidence supports its use with elbasvir for genotype 1 and 4 infection, while pharmacokinetic data explain its relevance to HIV/HCV coinfection therapy and chronic kidney disease and HCV treatment.

EZ Cap™ Firefly Luciferase mRNA Workflow Guide

2026-09-15

Use EZ Cap™ Firefly Luciferase mRNA as a sensitive, translation-focused reporter for delivery screening, gene regulation, and live-cell imaging. Its Cap 1 structure and optimized poly(A) tail support robust assay design, while reference-guided LNP testing helps distinguish particle quality from true biological potency.

Stiripentol: Practical LDH Inhibition Workflows

2026-09-14

Stiripentol enables direct, mechanism-focused LDH perturbation for seizure-metabolism studies and lactate-centered immunometabolic assays. This guide distinguishes LDH inhibition from MPC manipulation while providing practical preparation, assay, and troubleshooting strategies.